VelosBio Raises $137 Million Series B Funding For Cancer Drug Development
Monday, July 20, 2020
Photo courtesy of VelosBio. VelosBio’s pipeline seeks to produce novel targeted therapies across a broad range of cancers.
San Diego-based VelosBio, a company which is developing an antibody-drug conjugate that goes after a target of growing interest, has raised $137 million from venture capitalists...
Take 1 minute to subscribe and you'll get this story immediately, plus:
Already a subscriber? Sign in
- 52 weekly issues
- Subscriber-only digital content every business day, plus full access to SDBJ.com archives
- Book of Lists — the most comprehensive business resource in San Diego
- San Diego 500 — influential business leaders you need to know